Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F19%3A10399976" target="_blank" >RIV/00179906:_____/19:10399976 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11150/19:10399976
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=FbUXJT2pZm" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=FbUXJT2pZm</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.cllc.2018.11.002" target="_blank" >10.1016/j.cllc.2018.11.002</a>
Alternative languages
Result language
angličtina
Original language name
Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion
Original language description
Gene fusions involving the anaplastic lymphoma kinase gene (ALK) often leads to oncogenic activation of the ALK kinase resulting in tumor development in lung and other solid tumors. Accurate identification of the fusion gene in patients with lung cancer has profoundly impacted patients' clinical performance and long-term survival. In this report, we describe the discovery and the generation of a patient-derived tumor (PDX) model in mice for a lung adenocarcinoma with the rare STRNALK gene fusion. Using tissues from this PDX, we were able to perform extensive genomic analyses to fully characterize the molecular rearrangements resulted in this fusion gene. At more than 6 years post initial diagnosis, the patient continues to respond to tyrosine kinase inhibitor treatment despite systematic disease demonstrating the tumor is still sensitive to targeted therapy. In depth evaluation of the available reports on tumors with this same fusion suggested that 50 partner of the oncogenic ALK fusion may play a critical role affecting the long-term response to tyrosine kinase inhibitor therapy observed in this and other reported patients with the same fusion. Our clinical experience using PDX models to guide clinical treatment in advanced stage lung cancer are also discussed to help inform the design of similar clinical studies in the future.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Clinical Lung Cancer
ISSN
1525-7304
e-ISSN
—
Volume of the periodical
20
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
6
Pages from-to
"E142"-"E147"
UT code for WoS article
000459793100003
EID of the result in the Scopus database
2-s2.0-85058709738